OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I).
• Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors.
• Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL.
• OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors.
• FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis).
• Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024.
• ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation.
4 proprietary drug discovery platforms
• Pro-resolutive mAb platform
• Myeloid Checkpoint platform
• BiCKI® Platform
• mRNA Therapeutic platform f
Company Details
- Employees
- 82
- Founded
- -
- Address
- 22, Avenue Bénoni Goullin, Nantes,pays De La Loire 44200,france
- Phone
- 33143297857
- co****@****uno.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ose-immuno.com
- Keywords
- Immuno-oncologie, Immunothérapie, Maladies autoimmunes, NSCLC, Checkpoint inhibitor, Développement clinique, Biotechnologie, Néo-épitopes, SIRP-alpha, MDSC, Rectocolite hémorragique, Polyarthrite rhumatoïde.
- HQ
- NANTES, PAYS DE LA LOIRE
Ose Immunotherapeutics Questions
Ose Immunotherapeutics's helpline number is 33143297857
Ose Immunotherapeutics's website is ose-immuno.com
Ose Immunotherapeutics's LinkedIn profile is https://fr.linkedin.com/company/ose-immunotherapeutics
Ose Immunotherapeutics has
82 employees.
View email and phone details for 82
employees at Ose Immunotherapeutics.
Ose Immunotherapeutics's industry is
Biotechnology Research
Ose Immunotherapeutics's top competitors are
Genfit,
Innate Pharma,
Transgene,
Cellectis,
Maat Pharma,
Bioaster,
Valneva,
Abivax,
Xenothera,
Phaxiam Therapeutics.
Ose Immunotherapeutics's support email address is contact@ose-immuno.com
Ose Immunotherapeutics's categories are Biotechnology Research
Ose Immunotherapeutics's founding year is 2012
